Last reviewed · How we verify
NCT06838195
Clinical Trial of the S. Flexneri-S. Sonnei Bivalent Conjugate Vaccine
Phase 3 trial testing S. Flexneri-S. Sonnei bivalent conjugate vaccine in Dysentery in 8,000 participants. Participants enrolled and being followed up; not accepting new ones.
2 July 2028
Quick facts
| Lead sponsor | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd |
|---|---|
| Phase | Phase 3 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 8,000 |
| Start date | 12 May 2025 |
| Primary completion | 2 July 2028 |
| Estimated completion | 30 July 2028 |
| Sites | 1 location across Bangladesh |
Drugs / interventions tested
- S. Flexneri-S. Sonnei bivalent conjugate vaccine — full drug profile →
- Placebo
Conditions studied
- Dysentery — all drugs for Dysentery →
- Dysentery, Shigella — all drugs for Dysentery, Shigella →
Sponsor
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd — full company profile →
Who can join
Adults 6 Months to 5, any sex, with Dysentery or Dysentery, Shigella. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the protective efficacy of S. Flexneri-S. Sonnei bivalent conjugate vaccine against diarrhea caused by Shigella infection in infants and children aged 6 months to 5 years. Researchers will observe the incidence of diarrhea of any severity due to Shigella flexneri and Shigella sonnei infection 30 days after full immunization. The subjects will receive 2 doses of vaccination.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06838195
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd trials
Trials by the same sponsor.
- NCT06703203 — Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine · Phase 1, PHASE2 · completed
- NCT06970756 — A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60 · Phase 1 · not yet recruiting
- NCT06344065 — Immunogenicity and Safety of Diphtheria, Tetanus, Pertussis (DTaP) Vaccine in 3-month-old Infants · Phase 3 · recruiting
- NCT06314880 — Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) · Phase 1 · unknown
- NCT05939219 — Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06838195 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
- Last refreshed: 1 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06838195.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing